The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

In the wake of failed late-stage clinical trials last month for its novel retinal disease therapy, Melbourne-headquartered ...

Regal Partners has written off its entire investment in Opthea, which contributed to funds under management (FUM) taking an 8.3% hit in the March 2025 quarter.

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea (OTCPK:CKDXF) from Buy to ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea Limited - Depositary Receipt ...

Shares drop, US closes in on 104pc China tariff; RBNZ signals scope for further cuts; oil below $US61; iron ore at ...

A broker says this ASX biotech share potentially 'has no value from here', and reiterates the importance of diversification ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this healthcare stock.

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of insolvency and Novartis hired a new top lawyer.

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...